

# Alembic' acne therapy receives FDA final nod

Tretinoin cream is indicated for topical application in the treatment of acne vulgaris and has an estimated market size of \$ 94 million (~Rs 800 crore) in the US.



New Delhi: Alembic Pharmaceuticals announced that its Tretinoin cream, an acne vulgaris treatment, has received final approval from the US Food & Drug Administration (USFDA).

The approved drug is therapeutically equivalent to the reference listed drug product (RLD), Retin-A cream, marketed by Bausch Health US, LLC.

Tretinoin cream is indicated for topical application in the treatment of acne vulgaris and has an estimated market size of \$ 94 million (~Rs 800 crore) in the US for twelve months ending June 2025.

Post this approval the Gujarat-based drugmaker has a cumulative total of 224 ANDA approvals—202 final and 22 tentative approvals.

## News Source:

<https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/alembic-acne-therapy-receives-fda-final-nod/123365256>